Table II.

Comparison of main clinicopathological characteristics among the three groups.

	Patient no. (%)
Variables	Group I (n=211)	Group II (n=79)	Group III (n=58)	P-value
Gender				0.343
Male	171 (81.0)	59 (74.7)	43 (74.1)
Female	40 (19.0)	20 (25.3)	15 (25.9)
Age (years)				0.707
≤60	113 (53.6)	46 (58.2)	30 (51.7)
>60	98 (46.4)	33 (41.8)	28 (48.3)
Smoking history				0.738
Yes	148 (70.1)	59 (74.7)	42 (72.4)
No	63 (29.9)	20 (25.3)	16 (27.6)
Predicted FEV1				0.106
≤60%	27 (12.8)	4 (5.1)	9 (15.5)
>60%	184 (87.2)	75 (94.9)	49 (84.5)
Clinical T stage				0.002
T1	19 (9.0)	11 (13.9)	4 (6.9)
T2	131 (62.1)	32 (40.5)	33 (56.9)
T3	41 (19.4)	33 (41.8)	18 (31.0)
T4	20 (9.5)	3 (3.8)	3 (5.2)
Comorbidities				0.481
Yes	80 (37.9)	24 (30.4)	20 (34.5)
No	131 (62.1)	55 (69.6)	38 (65.5)
Clinical N2 levels				0.087
Single	187 (88.6)	62 (78.5)	49 (84.5)
Multiple	24 (11.4)	17 (21.5)	9 (15.5)
Clinical stage				0.252
IIIA	192 (91.0)	76 (96.2)	55 (94.8)
IIIB	19 (9.0)	3 (3.8)	3 (5.2)
Imaging response				<0.001
Objective response	199 (94.3)	7 (8.9)	58 (100.0)
Stable disease	12 (5.7)	72 (91.1)	0 (0.0)
Type of operation				<0.001
Lobectomy	132 (62.6)	27 (34.2)	22 (37.9)
Bilobectomy	37 (17.5)	11 (13.9)	7 (12.1)
Pneumonectomy	42 (19.9)	41 (51.9)	29 (50.0)
Histology				0.002
Adenocarcinoma	61 (28.9)	16 (20.3)	23 (39.7)
Squamous cell carcinoma	127 (60.2)	40 (50.6)	28 (48.3)
Adenosquamous carcinoma	17 (8.1)	20 (25.3)	6 (10.3)
Others	6 (2.8)	3 (3.8)	1 (1.7)
N downstaging				<0.001
Yes	211 (100.0)	0 (0.0)	0 (0.0)
No	0 (0.0)	79 (100.0)	58 (100.0)
Skip N2 metastasis				<0.001
Yes	0 (0.0)	32 (40.5)	28 (48.3)
No	211 (100.0)	47 (59.5)	30 (51.7)

FEV1; forced expiratory volume in 1 sec; CT, computed tomography.